NO942490L - Urease-basert vaksine mot Heliobacter-infeksjon - Google Patents

Urease-basert vaksine mot Heliobacter-infeksjon

Info

Publication number
NO942490L
NO942490L NO942490A NO942490A NO942490L NO 942490 L NO942490 L NO 942490L NO 942490 A NO942490 A NO 942490A NO 942490 A NO942490 A NO 942490A NO 942490 L NO942490 L NO 942490L
Authority
NO
Norway
Prior art keywords
urease
vaccine against
based vaccine
infection
heliobacter infection
Prior art date
Application number
NO942490A
Other languages
English (en)
Norwegian (no)
Other versions
NO942490D0 (no
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Haas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhle
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO942490(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of NO942490D0 publication Critical patent/NO942490D0/no
Publication of NO942490L publication Critical patent/NO942490L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO942490A 1992-11-03 1994-07-01 Urease-basert vaksine mot Heliobacter-infeksjon NO942490L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection
PCT/EP1993/003059 WO1994009823A1 (en) 1992-11-03 1993-11-02 Urease-based vaccine against helicobacter infection

Publications (2)

Publication Number Publication Date
NO942490D0 NO942490D0 (no) 1994-07-01
NO942490L true NO942490L (no) 1994-08-22

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942490A NO942490L (no) 1992-11-03 1994-07-01 Urease-basert vaksine mot Heliobacter-infeksjon

Country Status (29)

Country Link
US (1) US5972336A (zh)
EP (2) EP1170016A3 (zh)
JP (1) JPH07503255A (zh)
KR (1) KR100287424B1 (zh)
CN (1) CN1111429C (zh)
AT (1) ATE217196T1 (zh)
AU (2) AU678195C (zh)
BR (1) BR9305711A (zh)
CA (1) CA2127283A1 (zh)
CZ (1) CZ284416B6 (zh)
DE (1) DE69331901T2 (zh)
DK (1) DK0625053T3 (zh)
ES (1) ES2176232T3 (zh)
FI (1) FI112032B (zh)
GE (1) GEP20012429B (zh)
HU (1) HU219760B (zh)
IL (1) IL107474A (zh)
MX (1) MX9306841A (zh)
NO (1) NO942490L (zh)
NZ (2) NZ299149A (zh)
OA (1) OA10087A (zh)
PL (1) PL174448B1 (zh)
PT (1) PT625053E (zh)
RO (1) RO114870B1 (zh)
RU (1) RU2125891C1 (zh)
SG (1) SG70978A1 (zh)
SK (1) SK280619B6 (zh)
WO (1) WO1994009823A1 (zh)
ZA (1) ZA938203B (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
NZ314585A (en) * 1993-07-27 2000-08-25 Univ New South Wales Method of treating H. Pylori associated gastroduodenal disease
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
AUPM612494A0 (en) 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU696941B2 (en) * 1994-07-01 1998-09-24 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
DE69637947D1 (de) * 1995-04-28 2009-07-23 Merieux Oravax Snc Multimerer, rekombinanter urease impfstoff
AU6505796A (en) * 1995-07-26 1997-02-26 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1105159A2 (en) 1998-06-19 2001-06-13 Mérieux Oravax Lt and ct in parenteral immunization methods against helicobacter infection
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
AU8464398A (en) * 1998-07-16 2000-02-07 Cheil Jedang Corporation Urease based vaccine against (helicobacter) infection
AU771552B2 (en) * 1999-02-05 2004-03-25 Alk-Abello A/S Novel mucosal delivery system
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
CA2449670A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
KR100898648B1 (ko) * 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
JP2010508828A (ja) * 2006-11-10 2010-03-25 マーシャル，バリー，ジェー． 胃粘膜内へのペプチド送達方法及び装置
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
MX2016005822A (es) 2013-11-04 2016-12-02 Uti Limited Partnership Metodos y composiciones para inmunoterpia sostenida.
CA2984485A1 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
JPH06507494A (ja) * 1991-04-26 1994-08-25 カレノフ，エマニユエル 細菌性アレルゲンにより惹起される疾患の検出及び治療方法
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
EP0967279B1 (en) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
PL304419A1 (en) 1995-01-09
HU219760B (hu) 2001-07-30
PT625053E (pt) 2002-09-30
FI112032B (fi) 2003-10-31
FI943171A (fi) 1994-09-01
RO114870B1 (ro) 1999-08-30
EP0625053B1 (en) 2002-05-08
AU5561994A (en) 1994-05-24
PL174448B1 (pl) 1998-07-31
RU2125891C1 (ru) 1999-02-10
HUT69938A (en) 1995-09-28
ZA938203B (en) 1994-06-09
KR100287424B1 (ko) 2001-04-16
EP1170016A3 (en) 2002-03-06
ATE217196T1 (de) 2002-05-15
HU9402261D0 (en) 1994-10-28
FI943171A0 (fi) 1994-07-01
AU2003270987A1 (en) 2004-01-22
IL107474A0 (en) 1994-02-27
AU678195C (en) 2003-06-12
OA10087A (en) 1996-12-18
DE69331901D1 (de) 2002-06-13
NZ299149A (en) 1997-12-19
EP1170016A2 (en) 2002-01-09
SG70978A1 (en) 2000-03-21
AU678195B2 (en) 1997-05-22
DE69331901T2 (de) 2002-10-31
CZ284416B6 (cs) 1998-11-11
JPH07503255A (ja) 1995-04-06
CA2127283A1 (en) 1994-05-11
EP0625053A1 (en) 1994-11-23
GEP20012429B (en) 2001-05-25
WO1994009823A1 (en) 1994-05-11
DK0625053T3 (da) 2002-08-12
CZ160994A3 (en) 1995-04-12
SK280619B6 (sk) 2000-05-16
CN1111429C (zh) 2003-06-18
ES2176232T3 (es) 2002-12-01
IL107474A (en) 1998-09-24
NO942490D0 (no) 1994-07-01
SK79394A3 (en) 1996-09-04
MX9306841A (es) 1995-01-31
US5972336A (en) 1999-10-26
NZ258118A (en) 1997-04-24
BR9305711A (pt) 1997-02-18
CN1094640A (zh) 1994-11-09

Similar Documents

Publication Publication Date Title
NO942490D0 (no) Urease-basert vaksine mot Heliobacter-infeksjon
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
RU93058676A (ru) Оральное лечение геликобактерной инфекции
IT1237764B (it) Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CH614718A5 (en) Process for the preparation of glucosamine derivatives
FI851859A0 (fi) Antigenpreparat och isolering av saodana preparat.
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
DK1666057T3 (da) Fremgangsmåde til fremstilling af en acellulær vaccine indeholdende Bordetella pertussis antigener
NO991692L (no) Levende Heliobacter pylori-vaksine
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
EP0414816A4 (en) Induction of tolerance to a foreign antigen
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
ATE18007T1 (de) Hepatitisimpfstoff.
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
NO934547L (no) Oral behandling av Helicobacter-infeksjon
RU92016460A (ru) Вакцинная композиция, способ индукции иммунной реакции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application